

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the above-identified application. Please cancel claims 1-73.

Claims:

1. - 73. (Cancelled)

74. (New) A therapeutic composition comprising an amyloid-beta (A β) polypeptide linked to a therapeutic non-A β polypeptide, and a sterile pharmaceutically acceptable carrier or excipient,
wherein said therapeutic non-A β polypeptide improves or stabilizes one or more clinical features of a CNS disorder in a patient,
wherein the clinical features of a CNS disorder are selected from the group consisting of cognitive function, memory, behavior, language skills, motor skills and patient rigidity,
wherein the non-A β polypeptide is an antibody,
and wherein the antibody is polyamine modified.

75. (New) The composition of claim 74, wherein the antibody is a monoclonal polyamine modified antibody.

76. (New) The composition of claim 75 wherein the monoclonal polyamine modified antibody has specific binding affinity for amyloid comprising residues 1-39 of SEQ ID NO:1.

77. (New) The composition of claim 74, wherein the non-amyloid-beta (A β) polypeptide polyamine modified antibody is a humanized antibody.